Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05149768 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Open Label Extension Study of Brentuximab Vedotin in Early dcSSc

StatusCompleted
PhasePhase 2
Started2024-02-14
View on ClinicalTrials.gov ↗

Amendment history

2026-10-01
Trial completed
Final enrollment: 3 participants (planned 11)
Primary completion confirmed: July 2025 (last estimated February 2026)
2024-11-14
Study Status, Sponsor/Collaborators v6
Collaborators1 to 2 entries
SeagenSeattle Inc.Genetics (now a wholly owned subsidiary of Pfizer) Pfizer
2024-02-23
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v5
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2025-11-01→2026-02-14
Completion date2026-03-01→2026-07-01
Start dateestimated 2024-06-01→confirmed 2024-02-14
Study sites0→1
2023-12-12
Study Status v4
Start date2023-11-01→2024-06-01
2023-08-15
Study Status, Study Design v3
Primary completion date2024-03-01→2025-11-01
Completion date2024-06-01→2026-03-01
Start date2023-09-01→2023-11-01
Enrollment target10→11
Show 2 earlier versions
2023-03-07
Study Status v2
Start date2022-09-01→2023-09-01
2022-04-11
Study Status v1
Start date2022-03-01→2022-09-01
2021-11-24
Original filing
The purpose of this study is to assess safety and efficacy of Brentuximab vedotin, a CD30-directed antibody-drug conjugate, in patients with active diffuse cutaneous systemic sclerosis (dcSSc) who relapsed after discontinuation of Brentuximab vedotin.
Trial Details
NCT Number NCT05149768
Lead Sponsor London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborators: Seattle Genetics (now a wholly owned subsidiary of Pfizer), Pfizer
Conditions Diffuse Cutaneous Systemic Sclerosis
Enrollment 3 participants
Start Date 2024-02-14
Primary Completion 2025-07-23 (estimated)
Study Completion 2025-07-23 (estimated)
Updated on ClinicalTrials.gov 2026-09-30